Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 2 - Studien 11 bis 20 von insgesamt 40
- Rekrutierung läuftA Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden.Molekulare Marker
- Rekrutierung läuft
An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 (AHEAD-MERIT)
IndikationenMolekulare Marker - Rekrutierung läuftA Phase 2, Multicohort Open-Label study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy directed against BCMA in Subjects with Multiple Myeloma (68284528MMY2003)Molekulare Marker
- Rekrutierung läuftA prospective, multicentre phase-II trial of Acalabrutinib in very old (≥ 80y) or frail patients with treatment-naïve or relapsed/refractory CLL
- Rekrutierung läuftA Prospective, Open-Label, Multicenter Phase-2-Trial to Evaluate the Efficacy and Safety of Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients with Relapsed/Refractory CLLMolekulare Marker
- Rekrutierung läuftPhase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in patients with Cutaneous T cell lymphoma (CTCL)
- Rekrutierung läuftCombination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)Indikationen
- Rekrutierung läuftPhase II Trial for the Treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and BlinatumomabMolekulare Marker
- Rekrutierung läuftIntravenöse Eisencarboxymaltose versus orale Eisensubstitution bei Patienten mit metastasiertem kolorektalen Karzinom (CRC) und Eisenmangelanämie: eine randomisierte, multizentrische Therapieoptimierungsstudie
- Rekrutierung läuftA confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia